Mind Your Examples

06 July 2021 PharmaPatents Blog
Authors: Courtenay C. Brinckerhoff

In an unusual Federal Register Notice, the USPTO “reminded” applicants that “patent applications must properly present examples in a manner that clearly distinguishes between prophetic examples that describe predicted experimental results and working examples that report actual experimental results.” According to the USPTO, “The distinction must be clear to satisfy the written description and enablement requirements and comply with the applicant's duty of disclosure.”

Prophetic Examples versus Working Examples

In the Federal Register Notice, the USPTO distinguishes between “prophetic examples” which “describe experiments that have not in fact been performed,” and “working examples” which “correspond to work performed or experiments conducted that yielded actual results.” The Notice refers to MPEP guidance to the effect that “prophetic examples should not be described using the past tense,” but “may be written in future or present tense.”

Written Description and Enablement

The Federal Register Notice discusses the relationship between the presentation of examples and satisfaction of the written description and enablement requirements, while acknowledging that examples are not always required and that prophetic examples may be sufficient. However, the Notice warns:

[W]hen prophetic examples are described in a manner that is ambiguous or that implies that the results are actual, the adequacy and accuracy of the disclosure may come into question. If the characterization of the results, when taken in light of the disclosure as a whole, reasonably raises any questions as to whether the results from the examples are actual, the examiner will determine whether to reject the appropriate claims based on an insufficient disclosure under the enablement and/or written description requirements ….

Duty of Disclosure

The Federal Register Notice refers to two Federal Circuit decisions indicating that describing  examples that have not been carried out in a manner that suggests they were actually conducted raises inequitable conduct issues. The USPTO advises:

Distinguishing prophetic examples from working examples in a clear manner will avoid raising issues relating to the applicant's duty of disclosure.

Best Practices?

The Federal Register Notice outlines “best practices” that may go beyond the cited MPEP guidance. In addition to ensuring “the proper tense is employed to describe experiments and test results so readers can readily distinguish between actual results and predicted results,” the USPTO suggests:

It is a best practice to label examples as prophetic or otherwise separate them from working examples to avoid ambiguities.

Interestingly, the USPTO suggests making the distinction clear not just to the examiner, but also to “a person having ordinary skill in the art … including those who may not have the level of skill of the inventor” and to “the public.”

Changing Practices?

This Federal Register Notice is unusual, because the USPTO does not often publish “practice tips” in the Federal Register. It makes one wonder if the USPTO has seen an increase in prophetic examples not presented as such, or if a particular case has raised concerns. 

This blog is made available by Foley & Lardner LLP (“Foley” or “the Firm”) for informational purposes only. It is not meant to convey the Firm’s legal position on behalf of any client, nor is it intended to convey specific legal advice. Any opinions expressed in this article do not necessarily reflect the views of Foley & Lardner LLP, its partners, or its clients. Accordingly, do not act upon this information without seeking counsel from a licensed attorney. This blog is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Communicating with Foley through this website by email, blog post, or otherwise, does not create an attorney-client relationship for any legal matter. Therefore, any communication or material you transmit to Foley through this blog, whether by email, blog post or any other manner, will not be treated as confidential or proprietary. The information on this blog is published “AS IS” and is not guaranteed to be complete, accurate, and or up-to-date. Foley makes no representations or warranties of any kind, express or implied, as to the operation or content of the site. Foley expressly disclaims all other guarantees, warranties, conditions and representations of any kind, either express or implied, whether arising under any statute, law, commercial use or otherwise, including implied warranties of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Foley or any of its partners, officers, employees, agents or affiliates be liable, directly or indirectly, under any theory of law (contract, tort, negligence or otherwise), to you or anyone else, for any claims, losses or damages, direct, indirect special, incidental, punitive or consequential, resulting from or occasioned by the creation, use of or reliance on this site (including information and other content) or any third party websites or the information, resources or material accessed through any such websites. In some jurisdictions, the contents of this blog may be considered Attorney Advertising. If applicable, please note that prior results do not guarantee a similar outcome. Photographs are for dramatization purposes only and may include models. Likenesses do not necessarily imply current client, partnership or employee status.

Related Services

Insights

$4.24M Now the Average Cost Per Data Breach!
30 July 2021
Internet, IT & e-Discovery Blog
Podcast Episode 56: All Things Summer Associate Recruiting
30 July 2021
Foley Career Perspectives
Foley Podcast to Live Panel Discussion
29 July 2021
Foley Career Perspectives
End In Sight for Auto Shortage? Not So Fast
29 July 2021
Dashboard Insights
30th Annual Law of Product Distribution & Franchise Seminar
29 September | 7 & 20 October 2021
Milwaukee | Chicago | Dallas
7th National Telehealth Summit
4-5 October 2021
Miami Beach, FL
AHLA Fraud & Compliance Forum
21-22 September 2021
Baltimore, MD
2nd Clinical Trial Agreements Forum
16-17 September 2021
Online Livestream